Results 111 to 120 of about 420,437 (312)

5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells

Scientific Reports, 2017
Relapse and metastasis of nasopharyngeal carcinoma (NPC) are presumably attributed to cancer stem cells (CSCs). In recent years, chimeric antigen receptor (CAR)-modified immune effector cells have been shown to have impressive antitumour efficacy.
Xueyang Guo, Hang Zheng, Weiren Luo, Qianbing Zhang, Jingxian Liu, K. Yao   +5 more
semanticscholar   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials

Drug Design, Development and Therapy, 2017
Yan Wang,1 Benji Lv,2 Ke Li,3 Anqi Zhang,3 Hong Liu3 1Department of Clinical Laboratory, 2Department of Blood Transfusion, 3Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University ...
Wang Y, Lv BJ, Li K, Zhang AQ, Liu H
doaj  

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

OncoTarget, 2017
Background High recurrence rate after curative treatment is the major problem for hepatocellular carcinoma (HCC). Cytokine-induced killer cells (CIKs) therapy was extensively studied among HCC patients.
Xiurong Cai, Xing Li, Jin-xiang Lin, Tian‐tian Wang, M. Dong, Zhan-hong Chen, Chang-chang Jia, Ying-Fen Hong, Q. Lin, Xiangyuan Wu   +9 more
semanticscholar   +1 more source

Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells [PDF]

Cancer Biology & Therapy, 2012
The cytokine-induced killer cells (CIK) have been reported to have potent cytotoxicity against a variety of tumor cells including multiple myleoma (MM) cells. The mechanisms that CIK cell recognizing MM cells remain unknown. Recent studies indicated that the interaction between NKG2D receptor and NKG2D ligands plays an important role in inducing ...
Xuzhang, Lu, Aoshuang, Zhu, Xiaohui, Cai, Zhuxia, Jia, Wenmin, Han, Lingdi, Ma, Min, Zhou, Keqing, Qian, Lin, Cen, Baoan, Chen   +9 more
openaire   +2 more sources

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source

CIK Cell Therapy for Solid Tumor

Nano Biomedicine and Engineering, 2014
In recent years, the clinical trials on applying cytokine induced killer (CIK) cells to solid tumor therapy have been launched worldwide. CIK cells are a heterogeneous subset of ex-vivo expanded T lymphocytes, they present a mixed T-NK phenotype and are ...
Jingjing Zhang, Yao Yang, Hualin Fu
doaj   +1 more source

Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients

OncoTarget, 2017
Purpose To systematically evaluate the efficacy and safety of Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells (CIK/DC-CIK) immunotherapy in treating advanced colorectal cancer (CRC) patients.
Lei Zhang, Ying Mu, Anqi Zhang, Jiaping Xie, Shuangfeng Chen, Fang Xu, Wei-hua Wang, Ying-xin Zhang, Shaoda Ren, Changhui Zhou   +9 more
semanticscholar   +1 more source

Host‐Directed Biomaterials for Combatting Bloodstream Infections: From Macrocyclic Peptides to Immune‐Activating Cell Backpacks

Advanced Functional Materials, EarlyView.
Bloodstream infections (BSI) are one of the leading causes of mortality and morbidity in both civilian and military populations. This paper summarizes recent progress in novel treatment strategies to manage BSI arising from both bacterial and fungal pathogens using molecules, particles, and materials to elicit host‐directed immunity.
Thomas Thomou, Jagadish Krishnappa, Justin B. Schaal, Prasad Tongaonkar, Dat Q. Tran, Wenchao Gu, Yung‐Fu Chang, Michael E. Selsted, Shaoyi Jiang, Samir Mitragotri, Michael Super, Christopher J. Bettinger   +11 more
wiley   +1 more source